BACKGROUND: An understanding of the relationships among allelic variability and clinical outcomes will be critical if HIV-infected patients are to benefit from the explosion in knowledge in human genomics. Human DNA banks must allow future analyses while addressing confidentiality, ethical, and regulatory issues. METHOD: A multidisciplinary group of clinical investigators, ethicists, data managers, regulatory specialists, and community representatives developed Adult AIDS Clinical Trials Group (AACTG) Protocol A5128. Participants in past or present AACTG clinical trials may contribute DNA. Extraction from whole blood is performed at a central laboratory, where participants' unique identifiers are replaced by randomly assigned identifiers prior to DNA storage. To identify genotype-phenotype relationships, genetic assay results can be temporarily linked to clinical trials data. RESULTS: Institutional review boards in 21 states and Puerto Rico have approved Protocol A5128, and accrual is ongoing. Of the first 4,247 enrollees, 82% are male, 56% are white, 26% are African American, and 15% are Hispanic. Because participants may participate in multiple AACTG protocols, these represent 11,424 cases in 324 different AACTG studies and substudies, with at least 100 participants from 24 different studies. Studies exploring specific genotype-phenotype relationships are underway. CONCLUSION: The AACTG DNA bank will be an important resource for genomic discovery relevant to HIV therapy.
BACKGROUND: An understanding of the relationships among allelic variability and clinical outcomes will be critical if HIV-infectedpatients are to benefit from the explosion in knowledge in human genomics. Human DNA banks must allow future analyses while addressing confidentiality, ethical, and regulatory issues. METHOD: A multidisciplinary group of clinical investigators, ethicists, data managers, regulatory specialists, and community representatives developed Adult AIDS Clinical Trials Group (AACTG) Protocol A5128. Participants in past or present AACTG clinical trials may contribute DNA. Extraction from whole blood is performed at a central laboratory, where participants' unique identifiers are replaced by randomly assigned identifiers prior to DNA storage. To identify genotype-phenotype relationships, genetic assay results can be temporarily linked to clinical trials data. RESULTS: Institutional review boards in 21 states and Puerto Rico have approved Protocol A5128, and accrual is ongoing. Of the first 4,247 enrollees, 82% are male, 56% are white, 26% are African American, and 15% are Hispanic. Because participants may participate in multiple AACTG protocols, these represent 11,424 cases in 324 different AACTG studies and substudies, with at least 100 participants from 24 different studies. Studies exploring specific genotype-phenotype relationships are underway. CONCLUSION: The AACTG DNA bank will be an important resource for genomic discovery relevant to HIV therapy.
Authors: Todd Hulgan; Richard Haubrich; Sharon A Riddler; Pablo Tebas; Marylyn D Ritchie; Grace A McComsey; David W Haas; Jeffrey A Canter Journal: AIDS Date: 2011-01-02 Impact factor: 4.177
Authors: Marlene Smurzynski; Ann C Collier; Susan L Koletar; Ronald J Bosch; Kunling Wu; Barbara Bastow; Constance A Benson Journal: HIV Clin Trials Date: 2008 Jul-Aug
Authors: David W Haas; Yuki Bradford; Anurag Verma; Shefali S Verma; Joseph J Eron; Roy M Gulick; Sharon A Riddler; Paul E Sax; Eric S Daar; Gene D Morse; Edward P Acosta; Marylyn D Ritchie Journal: Pharmacogenet Genomics Date: 2018-07 Impact factor: 2.089
Authors: Jonathan M Carlson; Chanson J Brumme; Eric Martin; Jennifer Listgarten; Mark A Brockman; Anh Q Le; Celia K S Chui; Laura A Cotton; David J H F Knapp; Sharon A Riddler; Richard Haubrich; George Nelson; Nico Pfeifer; Charles E Deziel; David Heckerman; Richard Apps; Mary Carrington; Simon Mallal; P Richard Harrigan; Mina John; Zabrina L Brumme Journal: J Virol Date: 2012-10-10 Impact factor: 5.103
Authors: Daniel H Johnson; Charles Venuto; Marylyn D Ritchie; Gene D Morse; Eric S Daar; Paul J McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2014-04 Impact factor: 2.089
Authors: Samir K Gupta; Susan L Rosenkranz; Yoninah S Cramer; Susan L Koletar; Lynda A Szczech; Valerianna Amorosa; Stephen D Hall Journal: AIDS Date: 2008-10-01 Impact factor: 4.177
Authors: Zabrina L Brumme; Mina John; Jonathan M Carlson; Chanson J Brumme; Dennison Chan; Mark A Brockman; Luke C Swenson; Iris Tao; Sharon Szeto; Pamela Rosato; Jennifer Sela; Carl M Kadie; Nicole Frahm; Christian Brander; David W Haas; Sharon A Riddler; Richard Haubrich; Bruce D Walker; P Richard Harrigan; David Heckerman; Simon Mallal Journal: PLoS One Date: 2009-08-19 Impact factor: 3.240